Nebulized PL for Post-COVID-19 Syndrome

Nebulized PL for Post-COVID-19 Syndrome

Sponsored by Regenexx

This is a double-blind, randomized, placebo controlled single-center study using nebulized platelet lysate compared to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.


Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study type: Interventional (Clinical Trial) Estimated Enrollment: 40 participants Actual Study Start Date: August 3, 2020 Estimated Study Completion Date: December 30, 2021

Who is this study for?

  1. Aged 18-85
  2. Two weeks to 1-year post hospital discharge for COVID-19, which included 48 hours in ICU
  3. Ongoing activity intolerance due to breathing difficulties related to Acute Respiratory Distress Syndrome (ARDS)

What should I expect?

20 patients randomized to Treatment group: Inhaled nebulized platelet lysate (PL) 1x daily for eight weeks 20 patients randomized to Control group: Inhaled nebulized saline, 1x daily for eight weeks.

Outcomes will be measured at 4-weeks, 8-weeks, 3-months, 6- months

Participate in the Nebulized PL for Post-COVID-19 study

Thank you for your interest in advancing COVID-19 research.

Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.

If you have any difficulties or questions, please contact our support specialists at [email protected]

Have a question?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.